FGFR1, FGFR2 and FGFR3 all contribute to the generation of tumours in diverse cancer types that are in clinical trials for both selective and non-selective FGFR-inhibitors (Greulich and Pollock, 2011, Wesche et al., 2011, Sabnis and Bivona, 2013, Dieci et al., 2013). Here, FGFR1 is linked to neoplasm.